Episurf — Regulatory Filings 2021

Dec 13, 2021

Episurf Medical's implants approved for sale in Saudi Arabia

Episurf Medical (NASDAQ: EPIS B) today announces that the Saudi Food & Drug Authority (SFDA) has approved the company's implant technologies Episealer® Knee and Episealer® Talus for the Saudi market. Included in the approval is also the ankle device Talus Osteotomy Guide. The approval follows a review process.

"We are very happy that we are continuing to execute on our global strategy. Saudi Arabia is an exciting market. We have been looking at the Middle East region for several years, and I am pleased that we are now taking the next step in Saudi Arabia", says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be costefficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:15 CET on 13 December 2021.